Notwithstanding the complexity posed by multiple receptor–ligand interactions between the NK cells and GBM target cells, and the relatively small sample sizes, we found multiple differences in the expression of ligands for activation and inhibitory NK cell receptors. This evidence concerns the gene KLRD1 and glioblastoma.